Skip to main content

Advertisement

Figure 4 | BMC Cancer

Figure 4

From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Figure 4

Kaplan-Meier curves of DFS according to Ki67 (cut-off: 35%) in 196 HER2-negative luminal breast cancer patients. Of these 196 patients, nine developed recurrent disease during the median 29-month follow-up period. Despite the short observation period, DFS differed significantly between patients whose tumours had Ki67 expression higher than 35% versus lower than 35% (p < 0.01).

Back to article page